Скачать с ютуб Phase III CHARM trial of glibenclamide for large hemispheric infarction в хорошем качестве

Phase III CHARM trial of glibenclamide for large hemispheric infarction

Glibenclamide is a SUR1-TRPM4 channel blocker, shown in preclinical models and early clinical data to reduce cerebral edema following ischemic stroke. W. Taylor Kimberly, MD, PhD, Massachusetts General Hospital, Harvard Medical School, Boston, MA, comments of the results of the Phase III randomized, controlled CHARM study, which randomized patients with large hemispheric infarction to intravenous glibenclamide or placebo. Overall, there was no difference in functional outcomes at three months between the two groups. However, the drug was shown to be safe and a subgroup analysis indicated potential value of glibenclamide in patients with medium-large stroke volumes. Dr Kimberly highlights the importance of these data to inform future trials of the agent. This interview took place at the 10th European Stroke Organisation Conference (ESOC) 2024 in Basel, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.